Artelo Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 2.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.22M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company’s product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and inso...